Apellis Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
Apellis Pharmaceuticals CEO'su Cedric Francois, Sep2009 tarihinde atandı, in görev süresi 15.17 yıldır. in toplam yıllık tazminatı $ 10.37M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.1% maaş ve 92.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.38% ine doğrudan sahiptir ve bu hisseler $ 47.04M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 9.3 yıldır.
Anahtar bilgiler
Cedric Francois
İcra Kurulu Başkanı
US$10.4m
Toplam tazminat
| CEO maaş yüzdesi | 7.1% |
| CEO görev süresi | 15.2yrs |
| CEO sahipliği | 1.4% |
| Yönetim ortalama görev süresi | 5.8yrs |
| Yönetim Kurulu ortalama görev süresi | 9.3yrs |
Son yönetim güncellemeleri
Recent updates
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$250m |
| Jun 30 2024 | n/a | n/a | -US$333m |
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
| Sep 30 2019 | n/a | n/a | -US$228m |
| Jun 30 2019 | n/a | n/a | -US$194m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$4m | US$550k | -US$128m |
| Sep 30 2018 | n/a | n/a | -US$109m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$2m | US$400k | -US$51m |
Tazminat ve Piyasa: Cedric 'nin toplam tazminatı ($USD 10.37M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.60M ).
Tazminat ve Kazançlar: Cedric şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Cedric Francois (52 yo)
15.2yrs
Görev süresi
US$10,373,049
Tazminat
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$10.37m | 1.38% $ 47.0m | |
| Co-Founder & Director | 15.8yrs | US$495.96k | 0.62% $ 21.3m | |
| CFO & Treasurer | 7.1yrs | US$3.74m | 0.082% $ 2.8m | |
| Chief Operating Officer | less than a year | US$3.71m | 0.023% $ 776.6k | |
| General Counsel | 10.8yrs | US$4.89m | 0.092% $ 3.1m | |
| Chief Medical Officer | 1.8yrs | US$4.43m | 0.0050% $ 172.3k | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$3.08m | 0.90% $ 30.6m | |
| VP, Corporate Controller & Chief Accounting Officer | 3.3yrs | Veri yok | 0.0097% $ 333.1k | |
| Senior Vice President | no data | Veri yok | Veri yok | |
| Chief People Officer | 4.5yrs | Veri yok | 0.00071% $ 24.3k | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 2.5yrs | Veri yok | Veri yok | |
| Senior Vice President | 5.8yrs | Veri yok | Veri yok |
5.8yrs
Ortalama Görev Süresi
51.5yo
Ortalama Yaş
Deneyimli Yönetim: APLS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$10.37m | 1.38% $ 47.0m | |
| Co-Founder & Director | 15.2yrs | US$495.96k | 0.62% $ 21.3m | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 9.3yrs | Veri yok | Veri yok | |
| Independent Chairman of the Board | 11.3yrs | US$504.08k | 0.00054% $ 18.5k | |
| Independent Director | 11.3yrs | US$488.46k | 0.00054% $ 18.5k | |
| Member of AMD Scientific Advisory Board | 9.3yrs | Veri yok | Veri yok | |
| Member of PNH Scientific Advisory Board | 9.3yrs | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 9.3yrs | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$489.08k | 0.0046% $ 155.9k | |
| Independent Director | 14.7yrs | US$480.96k | 0.12% $ 4.0m | |
| Member of Pulmonology Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 9.3yrs | Veri yok | Veri yok |
9.3yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: APLS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).